Join medical oncologist, Aditya Bardia, MD, of University of California, Los Angeles, as he explores the evolving treatment landscape for patients with HR+, HER2- advanced and metastatic breast cancer. In this webinar, he reviews key clinical trial data on emerging oral SERDs and discusses practical strategies for integrating these therapies into evidence-based clinical practice.

Agenda

• Understand the current ET landscape
• Identify the unmet needs and challenges in MBC
• Explain the mechanisms of resistance, ESR1 mutations, and testing

After viewing this webinar, oncologists will be able to:

• Evaluate the evolving role of selective estrogen receptor degraders (SERDs) in the management of HR+, HER2- advanced or metastatic breast cancer
• Understand key clinical trial data to inform evidence-based sequencing and treatment considerations in endocrine-resistant disease
• Integrate emerging therapeutic strategies into clinical practice to optimize patient outcomes and personalize care decisions